matrix metalloproteinase inhibitors (Nippon Organon/Hokkaido University)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namematrix metalloproteinase inhibitors (Nippon Organon/Hokkaido University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase-1 inhibitorsMatrix metalloproteinase 9 inhibitorsMatrix metalloproteinase 3 inhibitors +[5] 
TargetsDisintegrin and metalloproteinase domain-containing protein 17Matrix metalloproteinase 9Matrix metalloproteinase 3 +[5] 
Therapy Area/IndicationsPsoriasisHeart FailureMultiple Sclerosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNippon Organon
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNippon OrganonHokkaido University
Active IndicationsN/A
Inactive IndicationsPsoriasisHeart FailureMultiple Sclerosis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A